🇺🇸 FDA
Patent

US 10766864

Morphinan derivatives for the treatment of neuropathic pain

granted A61PA61P25/04

Quick answer

US patent 10766864 (Morphinan derivatives for the treatment of neuropathic pain) held by Nektar Therapeutics expires Mon Sep 03 2040 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Nektar Therapeutics
Grant date
Tue Sep 08 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Sep 03 2040 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
8
CPC classes
A61P, A61P25/04